Spero Therapeutics Inc (SPRO NASDAQ) stock market data APIs
$1.0294
0(0%)
as of November 11, 2026
Try our APIs with
free plan!
Spero Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Prev. Close
1.0294
Open
1.0303
High
1.0571
Low
1.0189
52 wk Range
0.961-3.08
Market Cap
58 817 K
P/E Ratio
7.2143
Shares Outstanding
58 235 K
Revenue
46 997 K
Beta
1.564
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Spero Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Spero Therapeutics Inc data using free add-ons & libraries
Get Spero Therapeutics Inc Fundamental Data
Spero Therapeutics Inc Fundamental data includes:
- Net Revenue: 46 997 K
- EBITDA: 7 161 K
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: -0.14
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spero Therapeutics Inc News
New
Alphabet maintains massive SpaceX bet, initiates $548M Qualcomm stake
Alphabet (GOOG [https://seekingalpha.com/symbol/GOOG]) has maintained its long-standing investment in SpaceX (SPCX [https://seekingalpha.com/symbol/SPCX]) while adding a new $548 million position in Q...
Michael Burry is all-in on these stocks that have ‘corrected tremendously’ — and doubles down on AI shorts
The NASDAQ-100 hitting fresh all-time highs isn't fazing one of AI's biggest bears. In a recent Substack post, "Big Short" investor Michael Burry characterized the current state of the NASDAQ as "his...
Spero Therapeutics (SPRO) Q2 2026 Earnings Call Transcript
Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 5:00 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Esther Rajavelu Chief Medical Officer - Debra Zack Head of In...
Spero Therapeutics Inc (SPRO) (Q2 2026) Earnings Call Highlights: FDA Approval of Utebzi and ...
This article first appeared on GuruFocus. Cash and Cash Equivalents: $50.8 million as of June 30, 2026, excluding net proceeds from the July 2026 royalty financing. Revenue: No revenue for Q2 2026, c...
Get Spero Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.